Why Halozyme Therapeutics Is Trading 14% Higher Today
Halozyme Therapeutics (NASDAQ: HALO) was well in double-digit territory on Wednesday, as its stock was up by over 14% in mid-afternoon trading. That action followed the company's release of its latest set of quarterly results after market close the preceding day.
For its fourth quarter of 2020, Halozyme earned $121.7 million in revenue, more than double the $53.7 million of the year-ago quarter. On the bottom line, the biotech flipped to a profit of $73.2 million ($0.50 per share), compared to a Q4 2019 loss of $34.4 million.
Image source: Getty Images.
Source Fool.com
